# US 5,705,611 A · Human GM-CSF receptor component

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,705,611 A
- Document ID: US5705611A
- Status: Granted
- Kind: A
- Application number: 07/960,389
- Filed: 1993-01-07
- Granted: 1998-01-06
- Earliest claimed: 1990-07-18
- Assignees: Schering Corporation
- Inventors: Kazuhiro Hayashida; Toshio Kitamura; Atsushi Miyajima
- Web page: https://patentgrep.com/patent/US5705611A

## CPC

- C07K 14/715: for cytokines; for lymphokines; for interferons
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Nucleic acids encoding the .beta.-chain of the human granulocyte-macrophage colony stimulating factor (GM-CSF) receptor, as well as the .beta.-chain itself, are provided. The .beta.-chain may be expressed with the .alpha.-chain in cellular hosts to form compositions useful in screening agonists and antagonists of human GM-CSF.

## Claims

### Claim 1

A polypeptide substantially free of other non-receptor proteins comprising the extracellular and transmembrane domains of SEQ ID NO: 2.

### Claim 2 (depends on 1)

The polypeptide of claim 1, which is capable of operable association with a human GM-CSF receptor .alpha.-chain to form a GM-CSF receptor.

### Claim 3 (depends on 2)

The polypeptide of claim 2, wherein said receptor is capable of binding human GM-CSF with high affinity.

### Claim 4 (depends on 3)

The polypeptide of claim 3, wherein said high affinity provides a binding constant at least an order of magnitude less than a binding constant of either said polypeptide or .alpha.-chain alone.

### Claim 5 (depends on 3)

The polypeptide of claim 3 wherein said high affinity provides a binding constant of less than 1 nM.

### Claim 6 (depends on 3)

The polypeptide of claim 3, wherein said high affinity provides a binding constant of less than 200 pM.

### Claim 7 (depends on 1)

The polypeptide of claim 1 comprising residues 1 to 448 of SEQ ID NO: 2.

### Claim 8 (depends on 7)

The polypeptide of claim 7, which further comprises amino residues of 449 to 880 of SEQ ID NO: 2.

### Claim 9 (depends on 1)

The polypeptide of claim 1, substantially free of other human proteins.

### Claim 10 (depends on 1)

A composition of matter comprising the polypeptide of claim 1 in operable association with an .alpha.-chain, thereby forming a receptor which binds GM-CSF with high affinity.

### Claim 11 (depends on 10)

The composition of claim 10, which exhibits no specific binding to:
a) IL-2 at 1 nM;
b) IL-3 at 20 nM;
c) IL-4 at 1 nM;
d) IL-5 at 5 nM; or
e) EPO at 10 nM.

### Claim 12 (depends on 1)

The polypeptide of claim 1 which is the mature form of the amino acid sequence of SEQ ID NO. 2.

### Claim 13 (depends on 12)

The protein of claim 12 made in:
a) a mammalian cell;
b) an E. coli cell; or
c) a yeast cell.

### Claim 14 (depends on 12)

The protein of claim 12, which is capable of operable association with a human GM-CSF receptor .alpha.-chain to bind GM-CSF with high affinity.

### Claim 15 (depends on 14)

The protein of claim 14, wherein said high affinity provides a binding constant at least an order of magnitude less than a binding constant of either said polypeptide or .alpha.-chain alone.

### Claim 16 (depends on 14)

The polypeptide of claim 14, wherein said high affinity provides a binding constant of less that 1 nM.

### Claim 17 (depends on 14)

The polypeptide of claim 14, wherein said high affinity binding provides a binding constant of less that 200 pM.

### Claim 18

A recombinant polypeptide comprising the extracellular and transmembrane domains of SEQ ID NO: 2.

### Claim 19 (depends on 18)

The polypeptide of claim 18, wherein said polypeptide is expressed in:
a) a mammalian cell;
b) an E. coli cell; or
c) a yeast cell.

### Claim 20 (depends on 18)

The recombinant polypeptide of claim 18, comprising residues 1 to 448 of SEQ ID NO: 2.

### Claim 21 (depends on 18)

The recombinant polypeptide of claim 18 defined by the mature form of a GM-CSF receptor .beta.-chain of SEQ ID NO: 2.

### Claim 22 (depends on 21)

The polypeptide of claim 21, comprising residues 1 to 880 of SEQ ID NO: 2.

### Claim 23 (depends on 18)

The recombinant polypeptide of claim 18, capable of operable association with an .alpha.-chain of a human GM-CSF receptor.

### Claim 24 (depends on 18)

The recombinant polypeptide of claim 18, in operable association with an .alpha.-chain of a GM-CSF receptor.

### Claim 25 (depends on 24)

The recombinant polypeptide of claim 24, wherein said operable association provides binding of human GM-CSF with high affinity.

### Claim 26 (depends on 25)

The recombinant polypeptide of claim 25 wherein said high affinity provides a binding constant of less than 200 pM.